During the past decade, Instituto de Pesquisa clinica de Campinas conducted 38 clinical trials. In the 10-year time frame, 38 clinical trials started and 11 clinical trials were completed, i.e. on average, 28.9% percent of trials that started reached the finish line to date. In the past 5 years, 29 clinical trials started and 11 clinical trials were completed. i.e. 37.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto de Pesquisa clinica de Campinas" #1 sponsor was "Eli Lilly and Company" with 10 trials, followed by "Allergan" with 4 trials sponsored, "Boehringer Ingelheim" with 4 trials sponsored, "Hospital Israelita Albert Einstein" with 4 trials sponsored and "Amgen" with 4 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto de Pesquisa clinica de Campinas" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "CytoDyn, Inc." with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Bayer" with 1 trials as a collaborator and "George Clinical Pty Ltd" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Instituto de Pesquisa clinica de Campinas" are "COVID-19" (6 trials), "Obesity" (5 trials), "Diabetes Mellitus" (4 trials), "Gastroparesis" (4 trials) and "Heart Failure" (4 trials). Many other conditions were trialed in "Instituto de Pesquisa clinica de Campinas" in a lesser frequency.

Most popular intervention types in "Instituto de Pesquisa clinica de Campinas" are "Drug" (35 trials), "Other" (5 trials), "Dietary Supplement" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (25 trials), "Tirzepatide" (6 trials), "Empagliflozin" (3 trials), "Relamorelin" (3 trials) and "Baricitinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Instituto de Pesquisa clinica de Campinas" are 38 trials for "All" genders.

Currently, there are NaN active trials in "Instituto de Pesquisa clinica de Campinas". undefined are not yet recruiting, 10 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Instituto de Pesquisa clinica de Campinas, 3 suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto de Pesquisa clinica de Campinas, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 32 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".